| Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders |
53 |
| MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder |
39 |
| Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group |
22 |
| Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis |
22 |
| The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? |
21 |
| The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis |
21 |
| Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies |
18 |
| Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review |
17 |
| Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis |
17 |
| Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models |
16 |
| Multiple sclerosis registries in Europe - An updated mapping survey |
16 |
| Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis |
15 |
| Prognostic factors of disability in relapsing remitting multiple sclerosis |
15 |
| Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis |
14 |
| Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY) |
13 |
| Review: Patient-reported outcomes in multiple sclerosis care |
13 |
| Serious games for arm rehabilitation of persons with multiple sclerosis. A randomized controlled pilot study |
13 |
| Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis |
13 |
| How does cognition relate to employment in multiple sclerosis? A systematic review |
13 |
| Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis |
13 |
| Effects of exercise training on cytokines and adipokines in multiple Sclerosis: A systematic review |
13 |
| Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis |
12 |
| Efficacy of computer-based cognitive training in neuropsychological performance of patients with multiple sclerosis: A systematic review and meta-analysis |
12 |
| Potential mechanisms of action related to the efficacy and safety of cladribine |
12 |
| Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008-2018: A nationwide, population-based cohort study |
12 |
| Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence |
12 |
| Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US |
12 |
| Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders |
12 |
| Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination |
12 |
| Dysregulation of long non-coding RNA profile in peripheral blood of multiple sclerosis patients |
11 |
| Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review |
11 |
| Highly active multiple sclerosis: An update |
11 |
| Comparison of telemedicine versus in-person visits for persons with multiple sclerosis: A randomized crossover study of feasibility, cost, and satisfaction |
11 |
| Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers |
11 |
| Prevalence of multiple sclerosis in Poland |
10 |
| Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis |
10 |
| Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis |
10 |
| Metabolome-based signature of disease pathology in MS |
10 |
| Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support |
10 |
| Social cognition deficits and the role of amygdala in relapsing remitting multiple sclerosis patients without cognitive impairment |
10 |
| Multiple sclerosis risk factors contribute to onset heterogeneity |
10 |
| Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review |
9 |
| Evaluation of serum arsenic and its effects on antioxidant alterations in relapsing-remitting multiple sclerosis patients |
9 |
| Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study |
9 |
| Coexistence of Multiple Sclerosis and Alzheimer's disease: A review |
9 |
| Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience |
9 |
| Prevalence of asthma in multiple sclerosis: A United States population-based study |
9 |
| Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study |
9 |
| Pilates for people with multiple sclerosis: A systematic review and meta-analysis |
9 |
| The evolution of No Evidence of Disease Activity in multiple sclerosis |
9 |
